Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Primary Immune Deficiency: later-stage trial registry
2 of 6 indexed Primary Immune Deficiency trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #2,866 of 28,707 conditions by registered trial count.
6 US clinical trials · 2 currently recruiting · #2,866 of 28,707 conditions by registered trial count
Primary Immune Deficiency: 6 US clinical trials tracked, 2 recruiting.
Primary Immune Deficiency is the subject of 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is GC Biopharma, running 1 of these trials.
Enrollment posture brief
Registry condition primary-immune-deficiency
OPEN 2 | RECR 33% | LATE 3 | EARLY 0 | RANK #2866 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Primary Immune Deficiency lists 2 open slots (33% of 6 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Primary Immune Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Primary Immune Deficiency is recruiting below its size-band peers.
2 of 6 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Primary Immune Deficiency research.
GC Biopharma accounts for 1 of 6 trials (16.7%). 6 distinct sponsors appear on at least one study for this condition label.
-
Typical Primary Immune Deficiency enrolment sits around 100 participants.
Median target enrolment is 100 among the 6 trials that report a genuine target (sentinel values excluded). 3 of those (50%) plan for fewer than 100 participants.
-
Primary Immune Deficiency splits between interventional and observational designs.
3 interventional and 3 observational studies make up this index (50% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
6 total, page 1 of 1
Screening Protocol for Genetic Diseases of Lymphocyte Homeostasis and Programmed Cell Death
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00246857
Biologics And Clinical Immunology Cohort at Sinai
Icahn School of Medicine at Mount Sinai
NCT04784364
COVID-19 Vaccine Responses in PIDD Subjects
Duke University
NCT05321407
Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases
Octapharma
NCT04640142
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
GC Biopharma
NCT04565015
Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy
CSL Behring
NCT00419341
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Primary Immune Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Primary Immune Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Primary Immune Deficiency page
6 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Primary Immune Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- GC Biopharma sponsors the most Primary Immune Deficiency trials on record, review their full trial history before evaluating a specific study. See GC Biopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Immune Deficiency condition card totals 6 registered trials; most-linked intervention Human Normal Immunoglobulin for Subcutaneous Administration; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.